Overview of Price Target Adjustment#
Stifel has increased its price target for Ionis Pharmaceuticals (NASDAQ:IONS) from $83 to $86 while maintaining a Hold rating. Currently, the stock is trading at $74.82, reflecting a significant 141% increase over the past year. However, some analyses suggest that the shares may be overvalued at this price.
Tryngolza Pricing and Revenue Outlook#
Ionis Pharmaceuticals has proactively adjusted the pricing for its drug Tryngolza in anticipation of approval for a larger patient group suffering from sHTG (severe hypertriglyceridemia). This adjustment has impacted Tryngolza's performance in the first quarter of 2026. The company is forecasting a revenue decline in the second quarter as it transitions to an annual wholesale acquisition cost of approximately $40,000. However, Ionis expects to return to growth later in the year following the launch of the sHTG product. Analysts predict a 13% sales decline for the current year.
Upcoming Milestones and Market Potential#
The sHTG product has a crucial PDUFA (Prescription Drug User Fee Act) date set for June 30, which is when the FDA will decide on its approval. Ionis estimates that the sHTG product could generate peak sales exceeding $3 billion, based on its effectiveness in lowering triglycerides and reducing the risk of acute pancreatitis, along with anticipated broad access after discussions with payers.
Recent Earnings Performance#
In its first-quarter 2026 earnings report, Ionis Pharmaceuticals surpassed Wall Street expectations with an earnings per share (EPS) of -$0.56, which was better than the anticipated -$0.85, marking a 34.12% positive surprise. The company also reported revenue of $246 million, exceeding the forecast of $199.24 million. These results indicate strong performance and reflect investor confidence in Ionis Pharmaceuticals' strategic direction and financial health.